Novavax (NVAX) PT Reduced To $1.25 At Oppenheimer

March 19, 2019 7:24 AM EDT
Get Alerts NVAX Hot Sheet
Price: $237.54 +0.11%

Rating Summary:
    8 Buy, 4 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Oppenheimer analyst, Kevin DeGeeter, reiterated his Outperform on Novavax (NASDAQ: NVAX) but cut his price target to $1.25 (from $1.50) after NVAX reported 4Q18 financial results and provided important operating updates. The analyst offered 3 key takeaways:

1) disclosure that $40.8M was raised under ATM program in 1Q19 extending cash runway into late 2019, by our estimates

2) expectation for business development to move quickly once regulatory discussions are completed for ResVax and NanoFlu

3) optimism the current relationship with the Gates Foundation for ResVax can be extended

The analyst stated "Our base case assumes FDA seeks an additional study for ResVax prior to approval but the product is approved in the EU (or another jurisdiction) allowing for distribution of the product in developing markets".

For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.

Shares of Novavax closed at $0.52 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Earnings, FDA